Specifica

Specifica empowers companies that create cures with visionary antibody technologies.

[Specifica @SpecificaInc]

Interested in learning about our Gen 3 Library Platform? Our webinar “High Quality #Antibodies Straight From Selections” shares how the platform offers developability, extremely high diversity & the exclusion of sequence liabilities. #biotech https://t.co/hHxldZI908

[Specifica @SpecificaInc]

Our mission is to empower companies with visionary #antibody technologies. By using Next Generation Sequencing (#NGS) throughout construction & output analyses, we can directly measure the diversity of each exclusive library we build. #biotech
https://t.co/PvRUBLDoCl

[Specifica @SpecificaInc]

Via @GENbio, a look at #monoclonalantibodies, their biological complexities & the innovative new approaches for production and use, as the global therapeutic monoclonal #antibody market is expected to generate revenue of $300B by 2025. #biotech #antibodies https://t.co/ECSn9O9Hm9

[Specifica @SpecificaInc]

Why choose the Specifica platform? With visionary #antibody technologies, we're focused on empowering you to generate antibody drugs against any target, to create cures for any disease with our exceptional, exclusive #AntibodyLibraries. #antibodies
https://t.co/tPVLCCzXBO

[Specifica @SpecificaInc]

.@NewsMedical shared new research on #SARSCoV2, showing how closely the #antibodies formed in exposed humans resemble germline #antibody molecules which could lead to the development of novel antibody #therapeutics to counter the #pandemic. #covid19
https://t.co/c75huj2lwE

[Specifica @SpecificaInc]

Join CSO @Andrew0Bradbury & Head of Bioinformatics M Frank Erasmus for the webinar Using #NGS to Expand the Universe of Selectable #Antibodies." They'll examine the Gen 3 platform, which enables identification of leads with broad epitope coverage. #biotech
https://t.co/9NZsJiBx8I

[Specifica @SpecificaInc]

Join CSO @Andrew0Bradbury & Head of Bioinformatics M Frank Erasmus for @TheAbSociety’s webinar: #Antibody Discovery in the Cloud: Using #NGS to Expand the Universe of Selectable #Antibodies. We'll examine the use of NGS to build our libraries. #biotech
https://t.co/dpxVaDiu2B

[The Antibody Society @TheAbSociety]

Upcoming free webinar. Registration is open. @SpecificaInc @Andrew0Bradbury https://t.co/eDln43xNU0

[Specifica @SpecificaInc]

We believe there is tremendous value to fishing in your own #antibody “pond” when selecting therapeutic leads. That’s why we offer partners exclusive libraries, created from unique donor sets not used for any other library. #antibodies #biotech
https://t.co/DzIAKI91zQ

[Specifica @SpecificaInc]

A study in @NEJM of 12,500+ healthcare workers analyzed the extent to which those previously infected with #SARSCoV2 are protected from reinfection. Results: presence of anti-spike #antibodies was associated w/reduced risk in the ensuing 6 months. #biotech https://t.co/wliP754TR8

[Specifica @SpecificaInc]

Via @NPR: MDs encouraged by the use of #monoclonalantibodies as a #COVID19 treatment. Though there are logistical challenges, #healthcare professionals report success in deployment & results, emphasizing the value of #antibodies as therapeutics. #biotech
https://t.co/Tymsn4SoTu

[Specifica @SpecificaInc]

A final look back on 2020... This @nature article, co-authored by CSO @Andrew0Bradbury reviewed in vitro methods to generate recombinant animal-free #antibody alternatives within the metaphor of an “antibody iceberg.” #antibodies #biotech
https://t.co/sypnCalvYK

[Specifica @SpecificaInc]

Highlighting a great article from the past year. In this @nature piece by @metricausa, co-founder & CSO @Andrew0Bradbury shared insights on the benefits of recombinant #antibodies & naive antibody libraries. #antibody #biotech #biotechnology
https://t.co/nYef3NssqK

[Specifica @SpecificaInc]

Our goal in developing an #Antibody Discovery campaign is to generate as many different target-specific #antibodies as possible, w/the final product either a panel of antibodies in any format, or list of different antibody clonotype sequences. https://t.co/0ghNqSHuoB #biotech

[Specifica @SpecificaInc]

Great insights shared from Founder & CSO @Andrew0Bradbury during the recent @AntibodyEngIC Conference, where he & other industry leaders discussed “Antibody Selection & Screening in Early Discovery.” Full presentation replay available here: https://t.co/bhKrDsTWbZ #AntibodyEng

[Specifica @SpecificaInc]

The @nytimes shares a #coronavirus drug & treatment tracker, analyzing the most-talked-about treatments for the virus in terms of the evidence available, including the use of #monoclonalantibodies, #interferons & #convalescentplasma as treatments. https://t.co/NgXV4o301v #COVID19

[Specifica @SpecificaInc]

Comprised of five sub-libraries, our Generation 3 Library Platform has quality built in by design - offering developability, extremely high diversity, and the exclusion of sequence liabilities. https://t.co/c559JtybMy #antibodies #therapeutics #biotech

[The Seismic Collaborative @Seismic_PR]

.@SpecificaInc announced the delivery of an exclusive #antibodylibrary platform to @ucb_news, a #biopharma company focused on the development of medicines for people suffering from immune & central nervous systems disease. More in @medcitynews. https://t.co/gj4GWCysMz #clientnews

[Specifica @SpecificaInc]

Join @Andrew0Bradbury for the @AntibodyEngIC Virtual Conference, where he'll discuss #Antibody Selection & Screening in Early Discovery, 12/16 @ 12:15 EST, plus host an on-demand session on Drug-like #Antibodies Straight from Selections. https://t.co/6kBuYC3dVU #AntibodyEng

[Specifica @SpecificaInc]

As vaccines typically require years to produce, let's recognize the scientists who are racing to produce a safe & effective #coronavirus #vaccine by next year. It’s difficult to see how pharma can go back to taking years to generate vaccines & other drugs. https://t.co/4Q9wlXkQQg